Tenaya Therapeutics, Inc. financial data

Symbol
TNYA on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
11 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 608% % 7%
Debt-to-equity 22% % -2.3%
Return On Equity -85% % 4.6%
Return On Assets -70% % 4.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 216,998,876 shares 148%
Common Stock, Shares, Outstanding 216,760,283 shares 150%
Entity Public Float $63,100,000 USD -63%
Common Stock, Value, Issued $21,000 USD 162%
Weighted Average Number of Shares Outstanding, Basic 152,971,259 shares 80%
Weighted Average Number of Shares Outstanding, Diluted 152,971,259 shares 80%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $68,607,000 USD -21%
General and Administrative Expense $24,724,000 USD -15%
Operating Income (Loss) $93,331,000 USD 20%
Nonoperating Income (Expense) $2,734,000 USD -43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $90,597,000 USD 18%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $90,597,000 USD 18%
Earnings Per Share, Basic -0.59 USD/shares 55%
Earnings Per Share, Diluted -0.59 USD/shares 55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $100,547,000 USD 2226%
Cash, Cash Equivalents, and Short-term Investments $100,500,000 USD 64%
Other Assets, Current $1,025,000 USD 22%
Assets, Current $105,586,000 USD 57%
Property, Plant and Equipment, Net $27,672,000 USD -23%
Operating Lease, Right-of-Use Asset $9,417,000 USD -21%
Other Assets, Noncurrent $4,246,000 USD -12%
Assets $146,921,000 USD 22%
Accounts Payable, Current $3,581,000 USD -31%
Accrued Liabilities, Current $8,835,000 USD 10%
Liabilities, Current $15,436,000 USD -3.4%
Operating Lease, Liability, Noncurrent $7,810,000 USD -28%
Other Liabilities, Noncurrent $410,000 USD 46%
Liabilities $23,656,000 USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD -100%
Retained Earnings (Accumulated Deficit) $605,008,000 USD -18%
Stockholders' Equity Attributable to Parent $123,265,000 USD 33%
Liabilities and Equity $146,921,000 USD 22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $23,112,000 USD 19%
Net Cash Provided by (Used in) Financing Activities $50,259,000 USD 7.5%
Net Cash Provided by (Used in) Investing Activities $22,302,000 USD
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 216,760,283 shares 150%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $49,449,000 USD 263%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $100,966,000 USD 2029%
Deferred Tax Assets, Valuation Allowance $146,130,000 USD 16%
Deferred Tax Assets, Gross $148,527,000 USD 14%
Operating Lease, Liability $10,830,000 USD -20%
Payments to Acquire Property, Plant, and Equipment $383,000 USD -32%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $90,625,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid $13,116,000 USD -23%
Property, Plant and Equipment, Gross $67,605,000 USD -0.8%
Operating Lease, Liability, Current $3,020,000 USD 8.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,775,000 USD -2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,864,000 USD 0.08%
Operating Lease, Weighted Average Discount Rate, Percent 0.091 pure 2.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,286,000 USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,471,000 USD -61%
Deferred Tax Assets, Operating Loss Carryforwards $91,724,000 USD 38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200,000,000 shares 0%
Unrecognized Tax Benefits $7,257,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,515,000 USD 3%
Operating Lease, Payments $989,000 USD -26%
Additional Paid in Capital $728,252,000 USD 20%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $2,661,000 USD 23%
Deferred Tax Assets, Net of Valuation Allowance $2,397,000 USD -29%
Share-based Payment Arrangement, Expense $13,046,000 USD -21%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%